BioMarin Pharma (BMRN) Tops Q2 EPS by 61c ; Offers Guidance
Tweet
Share
E-mail
Get Alerts BMRN Hot Sheet
Price: $66.43 -0.81%
Revenue Growth %: +32.7%
Financial Fact:
Intangible asset amortization and contingent consideration: 9.65M
Today's EPS Names:
VIVO, PMCB, PLCE, More
Revenue Growth %: +32.7%
Financial Fact:
Intangible asset amortization and contingent consideration: 9.65M
Today's EPS Names:
VIVO, PMCB, PLCE, More
Join SI Premium – FREE
BioMarin Pharma (NASDAQ: BMRN) reported Q2 EPS of $1.44, $0.61 better than the analyst estimate of $0.83. Revenue for the quarter came in at $825 million versus the consensus estimate of $760.37 million.
GUIDANCE:
BioMarin Pharma sees FY2025 EPS of $4.40-$4.55, versus the consensus of $4.16. BioMarin Pharma sees FY2025 revenue of $3.12-3.2 billion, versus the consensus of $3.14 billion.
For earnings history and earnings-related data on BioMarin Pharma (BMRN) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Intel (INTC) PT Lowered to $92 at Mizuho
- Torrid Holdings Inc. (CURV) Tops Q2 EPS by 8c; Offers Guidance
- lululemon athletica (LULU) Tops Q2 EPS by $1.10, Cuts Guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
